Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Boosted by Raymond James & Associates

Raymond James & Associates raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 82,006 shares of the biopharmaceutical company’s stock after acquiring an additional 7,778 shares during the period. Raymond James & Associates owned 0.07% of Regeneron Pharmaceuticals worth $86,208,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in REGN. Brown Lisle Cummings Inc. grew its stake in Regeneron Pharmaceuticals by 18.2% during the 2nd quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 10 shares during the last quarter. Sachetta LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 10 shares during the period. Adirondack Trust Co. grew its position in shares of Regeneron Pharmaceuticals by 2.4% during the third quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after acquiring an additional 10 shares during the last quarter. UMB Bank n.a. increased its holdings in shares of Regeneron Pharmaceuticals by 1.1% in the 3rd quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after acquiring an additional 10 shares during the period. Finally, Team Hewins LLC lifted its position in Regeneron Pharmaceuticals by 2.5% in the 1st quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock valued at $434,000 after purchasing an additional 11 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on REGN shares. Leerink Partners restated a “market perform” rating and issued a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Canaccord Genuity Group reissued a “buy” rating and issued a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. JPMorgan Chase & Co. lifted their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. StockNews.com raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, October 9th. Finally, Argus raised their price target on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,116.00.

Insider Activity

In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares in the company, valued at $4,498,280. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $990.68 on Monday. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 1 year low of $769.19 and a 1 year high of $1,211.20. The company has a market cap of $109.16 billion, a PE ratio of 29.27, a PEG ratio of 3.45 and a beta of 0.12. The stock’s 50-day moving average price is $1,109.58 and its two-hundred day moving average price is $1,041.01.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same quarter in the previous year, the business earned $8.79 earnings per share. The firm’s revenue was up 12.3% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.85 EPS for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.